Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Featured Article Wall Street Loves FIGS. So Why Do Price Targets Predict a Pullback?Authored by Jennifer Woods. Published: 3/2/2026. After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has climbed back to a price it hasn't seen in nearly four years. The stock has surged nearly 260% over the past year, including a 58% rise in the last month alone. That rally has been fueled by strong earnings and a wave of bullish analyst commentary. Yet the consensus 12-month price target sits at just $12.25 — almost 30% below the current stock price. That gap raises a key question: how much of this recovery is supported by fundamentals, and how much is momentum? A closer look at FIGS' recent results and price action offers some clues. Early investors in FIGS saw a quick windfall after the company's May 2021 IPO at $22 per share; within a month the stock had jumped to $50. Demand for medical apparel during the COVID-19 pandemic helped fuel that run. As the pandemic waned, shares reversed sharply and were trading below $8 within 12 months. For the next few years, FIGS mostly traded in the single digits. After dipping below $4 in April 2025, however, the stock began another upward move. Earnings Momentum Sparks Rally Following steady gains after positive Q1 and Q2 2025 earnings, FIGS' Q3 2025 results, released Nov. 6, accelerated the rally. The report showed stronger-than-expected revenue growth, solid demand across its core businesses and healthy margins despite tariff headwinds. The company also issued an upbeat outlook, raising full-year guidance for net revenue and adjusted EBITDA margins. Wall Street reacted positively: the stock climbed more than 30% over the following week, and Zacks Research upgraded the shares to Strong Buy from Hold. In the next 3 minutes…
James Altucher – legendary investor and venture capitalist…
And someone who's known for playing his cards "close to the vest"…
Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO… Click here to watch this short 3-minute video now. Key Points - FIGS stock is up nearly 260% over the last year
- Strong earnings have fueled the rally
- Stock is trading almost 30% above the average price target
- Special Report: [Sponsorship-Ad-6-Format3]
The momentum continued after the Q4 2025 earnings report on Feb. 26. Q4 revenue jumped 33%, marking the company's best quarterly revenue — sales topped $200 million. Management highlighted strength across the business, including growth in active customers and higher average order values. Scrubwear, which accounted for more than three-quarters of net revenue, rose 35%, and international sales increased 55%. The quarter capped a strong year: full-year net revenue rose 14% year-over-year to a record $630 million. Despite tariff-related pressure on gross margin, profitability held up, with full-year adjusted EBITDA margin exceeding its target by more than 200 basis points. Earnings And Outlook Spark Analyst Support FIGS issued an upbeat outlook for fiscal 2026, expecting net revenue to grow 10%–12% and forecasting improved profitability. Management cited continued demand from healthcare hiring, plans to expand into new international markets, prioritized growth initiatives across businesses and an ongoing share buyback program. Analysts followed with a flurry of upgrades and more bullish coverage. Barclays raised its rating to Strong Buy from Hold, KeyCorp moved to Overweight from Sector Weight with a $17 target, and Goldman Sachs shifted to Hold from Strong Sell. BTIG reiterated Buy with a $15 target, and Telsey Advisory raised its target to $15 from $9. FIGS Stock Pushes Past Price Targets Strong earnings have been the clear catalyst behind FIGS' move to four-year highs. Shares began climbing ahead of the Q4 report, jumping nearly 14% in the session before the release. After the results, the rally intensified: the stock surged 24% on the first trading day following the report and added another 10% the next day. As of March 4, the stock was trading above $17, roughly 30% higher than the average 12-month price target of $12.25 based on 10 analyst reports. That level also exceeds Morgan Stanley's $8 target issued in January and tops KeyCorp's $17 target. The gap between upbeat analyst commentary and relatively modest price targets suggests analysts like FIGS' improving fundamentals but remain cautious about valuation. At current levels, shares trade at a price-to-earnings ratio near 90, implying much of the company's anticipated growth is already priced in. Investors may therefore be celebrating the turnaround, but skepticism remains about whether the stock can sustain further gains or if a pullback is possible.
| 
